uniQure (NASDAQ:QURE) Stock Price Down 4.9% After Analyst Downgrade

uniQure N.V. (NASDAQ:QURE)’s share price dropped 4.9% during trading on Monday after Barclays lowered their price target on the stock from $31.00 to $25.00. Barclays currently has an equal weight rating on the stock. uniQure traded as low as $15.56 and last traded at $15.3020. Approximately 728,277 shares were traded during trading, a decline of 79% from the average daily volume of 3,510,736 shares. The stock had previously closed at $16.09.

Other analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Tuesday, March 10th. Sanford C. Bernstein cut uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, The Goldman Sachs Group reduced their price objective on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Insider Activity

In other uniQure news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. This trade represents a 23.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares in the company, valued at $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last 90 days. Company insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently modified their holdings of the company. Private Trust Co. NA purchased a new position in uniQure during the 3rd quarter worth $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the third quarter worth approximately $50,000. Torren Management LLC purchased a new stake in shares of uniQure during the fourth quarter worth approximately $28,000. Finally, FNY Investment Advisers LLC increased its stake in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Stock Performance

The company has a market cap of $962.59 million, a PE ratio of -4.45 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The stock’s 50-day simple moving average is $20.59 and its 200 day simple moving average is $29.64.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, equities analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.